Gene · 5426
POLE: DNA polymerase epsilon, catalytic subunit
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. POLE: DNA polymerase epsilon, catalytic subunit. Genes, record 5426. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5426
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q07864 | DNA polymerase epsilon catalytic subunit A | 2,286 | 18 | Ensembl, GeneID, HGNC |
Source UniProt
Patents29
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 58447 | Q07864 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 5443 | Q07864 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 5047 | Q07864 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 5047 | Q07864 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 5443 | Q07864 | Espacenet |
| JP 2025039500 A | 2025-03-21 | 1 | Q07864 | Espacenet |
| US 12173335 B2 | 2024-12-24 | 48 | Q07864 | Espacenet |
| EP 4464338 A2 | 2024-11-20 | 331 | Q07864 | Espacenet |
| EP 4464338 A2 | 2024-11-20 | 335 | Q07864 | Espacenet |
| US 11680268 B2 | 2023-06-20 | 331 | Q07864 | Espacenet |
1 to 10 of 29
See all 29 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ASPACYTARABINE | CHEMBL4297599 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| CLOFARABINE | CHEMBL1750 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| CYTARABINE | CHEMBL803 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| FLUDARABINE PHOSPHATE | CHEMBL1096882 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE | CHEMBL888 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE HYDROCHLORIDE | CHEMBL1637 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| TROXACITABINE | CHEMBL359164 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
Trials4,186
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | GEMCITABINE | PHASE3 | ClinicalTrials.gov | |
| NCT07604233 | CYTARABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07603557 | FLUDARABINE PHOSPHATE | PHASE2 | ClinicalTrials.gov | |
| NCT07602140 | GEMCITABINE | PHASE2 | ClinicalTrials.gov | |
| NCT07598318 | GEMCITABINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07588360 | CYTARABINE | ClinicalTrials.gov | ||
| NCT07583888 | CYTARABINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07579195 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07575191 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07570849 | GEMCITABINE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 4,186
See all 4,186 trialsNIH grants310
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | POLE papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 10 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 4 | 2025 |
| P30CA036727 | Buffett Cancer Center Support Grant | 3 | 2025 |
| R01ES028271 | Investigation of human DNA polymerase epsilon variants | 3 | 2025 |
| ZIAAI000646 | Transgenic Animal Models Of Human Immune Defects | 3 | 2025 |
| ZIAAI000647 | Genes And Gene Products As Immunoadjuvants | 3 | 2025 |
| P20GM103427 | Nebraska Research Network in Functional Genomics | 2 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016359 | Cancer Center Support Grant | 2 | 2025 |
| P30CA047904 | Cancer Center Support Grant | 2 | 2025 |
1 to 10 of 310Source NIH's project files
See all 310 nih grantsPapers392
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review. | Crit Rev Oncol Hematol | 2026 | 42386138 | PubTator, text mining | PubMed |
| Functional Characterization of POLE1 Variant Fibroblasts Reveals Replication Stress and Increased Sensitivity to Genotoxic Stress. | Diseases | 2026 | 41891994 | PubTator, text mining | PubMed |
| Leveraging sequences missing from the human genome to diagnose cancer. | Commun Med (Lond) | 2025 | 40841759 | PubTator, text mining | PubMed |
| Ultrasound and gene-guided microwave ablation vs. surgery for low-risk papillary thyroid carcinoma: a prospective observational cohort study. | Precis Clin Med | 2025 | 40385102 | PubTator, text mining | PubMed |
| ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability-high (MSI-H) molecular subtype. | Mol Oncol | 2024 | 39031567 | PubTator, text mining | PubMed |
| Immunotherapy for Solitary Fibrous Tumor (Hemangiopericytoma): A Unique Treatment Approach for a Rare Central Nervous System Tumor. | Neurologist | 2024 | 38797934 | PubTator, text mining | PubMed |
| Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer. | Heliyon | 2024 | 38496877 | PubTator, text mining | PubMed |
| Race, Prevalence of POLE and POLD1 Alterations, and Survival Among Patients With Endometrial Cancer. | JAMA Netw Open | 2024 | 38231514 | PubTator, text mining | PubMed |
| Antagonistic interactions safeguard mitotic propagation of genetic and epigenetic information in zebrafish. | Commun Biol | 2024 | 38182651 | PubTator, text mining | PubMed |
| Congenital anaemia associated with loss-of-function variants in DNA polymerase epsilon 1. | J Med Genet | 2024 | 37833059 | PubTator, text mining | PubMed |
1 to 10 of 392
See all 392 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5426
GET https://conductscience.org/api/genes/v1/5426/patents?page=2